Result of General Meeting

Premaitha Health plc

("Premaitha" or the "Company")

Result of General Meeting

Manchester, UK - 10 January 2017: Premaitha Health plc (AIM: NIPT), developer of a leading CE-marked non-invasive prenatal screening system, announces, further to the announcement made on 21 December 2016 in respect of the conditional acquisition of Yourgene Bioscience (the "Announcement"), that at its General Meeting held earlier today, all resolutions were duly passed. Unless the context otherwise requires, words and expressions defined in the Announcement have the same meanings in this announcement.

Accordingly, shareholders have approved the acquisition of Yourgene and the share sub-division referred to in the Announcement.

The Acquisition remains conditional on the granting of the regulatory approval of the Acquisition required by Taiwanese law and the London Stock Exchange agreeing to admit (subject only to their allotment) the Acquisition Shares (being 76,054,570 ordinary shares in the Company) to trading on AIM.

The Company's new ordinary shares of 0.1p each are expected to be admitted to trading on AIM ("Admission") at 8:00 a.m. on 11 January 2017. The Company's ISIN and SEDOL codes remain unchanged.

Following Admission, the Company's total issued and voting share capital will comprise 228,163,709 ordinary shares of 0.1p each. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in, or a change to their interest in, the Company.

For more information, please contact:

About Premaitha

Premaitha is a molecular diagnostics company which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved non-invasive screening tests for pregnant women.

Premaitha's lead test - the IONA® test - was launched in February 2015 and is the leading CE marked complete system which estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions. The IONA® test is performed on the mother's blood sample - which contains traces of fetal DNA - and then analysed using next generation DNA sequencing technology from ThermoFisher Scientific.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary stressful and invasive follow up diagnostic procedures which are costly, resource intensive and carry a risk of miscarriage.

Non-invasive prenatal screening is an emerging, multi-billion dollar global market and Premaitha's complete CE Marked system enables laboratories and health care practitioners to offer an approved, non-invasive prenatal screening system in-house.

Premaitha is based in Manchester Science Park, United Kingdom and its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.